Neimeth International Pharmaceuticals Plc is seeking shareholder approval for a N1.98 billion capital restructuring that could significantly reshape its balance sheet and future dividend capacity.
The move follows a February 5, 2026, order of the Federal High Court directing the company to convene a Court-Ordered Meeting (COM) to consider a Scheme of Arrangement. The virtual meeting is scheduled for March 31, 2026.
While the proposal is largely technical, its implications are strategic.
